Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,654.00-0.13%ETH$2,677.39-1.09%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
KU

NASDAQ · KURA

Kura Oncology, Inc.

Healthcare · Biotechnology

$10.65

Up+$0.00 (+0.00%)

Updated Oct 5, 2026, 1:13 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
911.06M
P/E ratio
-4.23
Dividend yield
0.00%
52-week range
$7.54 – $13.90
Volume
1.89M
Avg. volume
1.89M

Price performance · KURA

KURA price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 2, 2026

KURA closed at $10.65 after 19 trading sessions, down 14.94% for the selected period.

Last close
$10.65
Period change
-14.94%
Period low
$10.61
Period high
$12.52
Daily close
View OHLC price history
KURA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 2, 2026$10.85$10.97$10.59$10.651.89M
Oct 1, 2026$11.10$11.125$10.59$10.652.43M
Sep 30, 2026$10.90$10.95$10.605$10.711.87M
Sep 29, 2026$10.65$10.905$10.54$10.8051.89M
Sep 28, 2026$10.71$10.83$10.36$10.611.65M
Sep 25, 2026$10.88$10.96$10.75$10.761.23M
Sep 24, 2026$11.00$11.075$10.66$10.861.77M
Sep 23, 2026$11.73$11.81$10.825$11.042.77M
Sep 22, 2026$11.80$11.985$11.5848$11.731.68M
Sep 21, 2026$11.86$11.998$11.49$11.601.76M
Sep 18, 2026$11.64$11.84$11.56$11.732.67M
Sep 17, 2026$11.39$12.20$11.35$11.721.85M
Sep 16, 2026$11.31$11.52$11.14$11.201.79M
Sep 15, 2026$11.48$11.48$11.025$11.301.83M
Sep 14, 2026$11.37$11.68$11.25$11.561.46M
Sep 11, 2026$11.58$11.75$11.335$11.392.12M
Sep 10, 2026$12.00$12.00$11.4409$11.571.81M
Sep 9, 2026$12.50$12.6063$11.99$12.092.21M
Sep 8, 2026$12.925$12.925$12.50$12.521.51M

Latest KURA news

The latest Smart Investors Daily articles mentioning KURA.

Stock researchCompany · Overview

KURA research

Overview

Company profile and research snapshot.

Company profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.33
Implied upside
—
Analysts
—
KURA recent ratings
DateFirmRatingTarget
Oct 1, 2026JP MorganOverweight—
Aug 24, 2026CitizensMarket Outperform—
Aug 13, 2026WedbushOutperform—
Jul 28, 2026WedbushOutperform—
Jun 15, 2026CitizensMarket Outperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

– KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models – – KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide – – Findings highlight a potentially disease-modifying approach designed to restore the body’s own endogenous insulin-producing capacity – – Caspian is building a leadership position in menin-direct

Benzinga · Sep 17, 2026

Kura Oncology Q2 2026 Earnings Call Transcript

On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By